Pembrolizumab trials for Metastatic Triple-Negative Breast Carcinoma

All Pembrolizumab trials · All Metastatic Triple-Negative Breast Carcinoma trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Metastatic Triple-Negative Breast Carcinoma

• A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
  NCT06246968 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
  NCT04348747 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 3 locations
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
  NCT05318469 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
  NCT06324240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
  NCT05741164 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations

Common questions

How many trials study Pembrolizumab for Metastatic Triple-Negative Breast Carcinoma?

8 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.